Lipid Management — UKMLA MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: D — The non-HDL reduction is about 31%, so consider dose intensification
Baseline non-HDL cholesterol is 6.5 minus 1.3, or 5.2 mmol/L. The repeat value is 4.8 minus 1.2, or 3.6 mmol/L. The reduction is therefore 1.6 divided by 5.2, approximately 31%, which is below the greater-than-40% reduction sought for primary prevention. After confirming adherence, timing and lifestyle measures, NICE advises considering an increased atorvastatin dose up to the maximum tolerated and appropriate dose. A small HDL change is not a reason to abandon effective risk reduction.
Reference: NICE NG238, assessing response to statin treatment. https://www.nice.org.uk/guidance/ng238/chapter/recommendations